Health Trials

Advanced or Metastatic NSCLC

2

Review clinical trials related to Advanced or Metastatic NSCLC. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC

This is a randomized, controlled, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of oral HS-10504 monotherapy versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC harboring EGFR C797S mutation after failure of EGFR TKI therapy.

Participants needed: 206
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.Updated: Aug 10, 2026
Eligibility criteria

Age ≥18 years. [+3]

Presence of other well-documented driver gene mutations (e.g., ALK fusion, ROS1... [+14]

Read more
Status: Recruiting

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.

Participants needed: 354
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.Updated: Nov 4, 2024Locations: 1
Eligibility criteria

Men or women greater than or equal to 18 years. [+8]

Previous or current treatment with EGFR C797S inhibitors. [+14]

Read more